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A utoantibodies directed against the islet cells of the pancreas are an important hallmark of type I (insulin-dependent) diabetes mellitus. Besides, significance in research studies probing the mechanism(s) of autoimmune beta cell destruction, islet cell antibody assays are currently finding increasing application in clinical diabetology. In particular, recent reports indicate that islet cell antibodies are an important predictive marker of ongoing preclinical beta cell destruction. 14 In combination with serial assessments of sensitive indices of beta cell mass/function, like the early-phase insulin release to i.v. glucose, islet cell antibody assays are crucial for monitoring the natural history and chronology of the beta cell destructive process. In addition, in subjects with a history of gestational diabetes mellitus 356 and in patients with non-insulin-dependent diabetes mellitus, 78 presence of islet cell antibodies portend the subsequent development of insulin dependence, thus providing valuable information for clinical management. Recent observations suggest that islet cell antibody assays may also prove to be useful in the field of pancreas/islet transplantation, particularly in the differential diagnosis of recurrent autoimmune insulitis 9 versus rejection and other causes of graft dysfunction and failure.
Despite its original discovery, in 1974, 1011 and numerous attempts at improvement and modification, 1217 conventional, indirect immunofluorescence and other immunocytochemical assays for islet cell antibodies are beset with numerous methodologic problems, and these have precluded satisfactory standardization of this useful assay procedure. At the current state of knowledge regarding the biochemistry and molecular characteristics of the relevant islet cell "target" autoantigens, the indirect immunofluorescence assay continues to be the best available and clinically relevant measurement for circulating islet cell antibodies. The inevitable need for a fresh frozen, unfixed human pancreatic substrate (from surgical specimens or cadaveric transplant donors) has been amply emphasized in the literature. However, other impeding factors include the high background acinar pancreatic staining and the gross batch-to-batch variability in the quality of the second-step-conjugated antibody (antihuman immunoglobulin) reagent used in the assay. We have observed that use of an optimal dilution of fluoresceinconjugated protein A as a "nonantibody," chemical probe to detect human immunoglobulin binding to the pancreatic islet eliminates many of the problems encountered in the assay and facilitates standardization.
The advantages provided by this technique have led us to completely switch from the conventional second-step antibody method to the ICA by the protein A system (ICA-pA) as described in this article. In addition, microphotometric techniques have been used to quantitate circulating serum islet cell antibodies using this assay system.
MATERIALS AND METHODS

HUMAN PANCREATA
These were obtained from cadaveric kidney transplant donors and surgical pancreatectomy specimens. Half-centimeter blocks were snap frozen in precooled isopentane on dry ice and stored at -70°C. Thin cryostat sections (4-5 fjim) were cut onto gelatin dichromate-coated slides before use. (Such slides have been found to withstand storage at -20°C for several months.) HUMAN SERA Sera from type I diabetic subjects, first-degree relatives of type I diabetic subjects, and controls were stored at -20°C before use. (4) FITC-conjugated goat antihuman IgM, mu-chain specific, affinity isolated (#2192, Tago, Inc.). FITC-conjugated protein A. Protein A used in these experiments was prepared from Staphylococcus aureus (Cowan strain) using ion exchange and gel filtration chromatography, 18 and then labeled with fluorescein isothiocyanate. 19 The final preparation had an immunoglobulin binding capacity of 9.7 mg human IgG/mg protein and contained 70.5 |jig FITC/mg protein (Sigma, St. Louis, Missouri, #P-5145).
SECOND-STEP REAGENTS
INDIRECT IMMUNOFLUORESCENCE Human pancreatic sections were incubated for 30 min at room temperature with undiluted human sera. The sections were washed twice with phosphate-buffered saline containing 0.05% sodium azide (PBS), and incubated for 30 min at room temperature with suitable dilutions of the second-step reagents (FITC-conjugated antihuman immunoglobulins 1:20 or FITC-conjugated protein A 1:1000, both diluted in PBS with 1% bovine serum albumin). The sections were washed twice in PBS, mounted in PBS with 30% glycerol, and examined under a Leitz Dialux or Diavert fluorescence microscope (Rockleigh, New Jersey). The relative intensity of islet immunofluorescence was graded on an arbitrary visual scale of 0-4, based on the subjective assessment of differential staining between the islet and the background acinar tissue.
MICROIMMUNOFLUOROMETRY
Quantitation of specific islet cell immunofluorescence was performed using a Leitz MPV compact photometer. The diameter of the photometer-measuring diaphragm was preset (to encircle the cross section of few islet cells in the field of interest to be measured) and held constant for all measurements ( Figure 1F ). During the actual quantitation of islet immunofluorescence, the pancreatic sections were systematically scanned from one edge to the other (Figure 2A ). Coupled measurements of fluorescent intensity were obtained on the islet and on the adjacent acinar pancreas, and the difference between the two readings provided a measurement of specific islet cell immunofluorescence. A minimum of 10 sets of readings was obtained for every serum sample tested, and the results were automatically recorded and statistically analyzed by a Hewlett-Packard (Andover, Massachusetts) 97S I/O calculator connected to the photometer.
MONOCLONAL ANTIBODY COUNTERSTAINING Monoclonal islet cell antibody BISL-32 was purified and directly conjugated with the alternative fluorochrome tetramethyl rhodamine B isothiocyanate (TRITC). During the final step in the immunofluorescence procedure, a 1:1000 dilution of the reagent (immunoglobulin concentration 10 mg/ ml) was added onto the pancreatic sections.
RESULTS
In marked contrast to the polyclonal antihuman immunoglobulin reagents derived from various immunized animal sera, the use of an FITC-conjugated protein A as a standard, "nonantibody," second-step reagent eliminated much of the background exocrine pancreatic staining (Figure 1, A-E) . This rendered the visual assessment of positive or negative islet staining easier and more convenient. By the FITC protein A (ICA-pA) technique the islets stood out clearly, brightly stained against a dark background (Figure 1, E and F) , whereas, with the use of the anti-immunoglobulin antibody reagents, varying degrees of background staining of the acinar pancreatic cells (Figure 1 , A-D) interfered with the visual assessment of the islet cell antibody positivity or negativity, as read by two independent observers. Table 1 illustrates the results of the ICA measurements by our new assay system (ICA-pA) on serum samples previously characterized in our laboratory by the conventional immunofluorescence assays using polyclonal anti-immunoglobulin antibody conjugates. In particular, there were no false negatives in the ICA-pA assay as compared with the results from the conventional assay. At the same time, the assessment of borderline and weak positive readings was made much easier by the new technique. Figure 2 illustrates the data on the microimmunofluorometric quantitation of islet cell antibodies. Use of an optimal dilution of the fluorescein-conjugated protein A stock solution ( Figure 2B ) is crucial to obtain the highest signal (islet)/noise (acinar background) ratio and, thus, the maximum sensitivity. Standard curves were generated using dilutions of reference islet cell antibody positive sera ( Figure 2C ). Repeated exposure of the same field must be avoided during the photometric quantitation to eliminate the effects of rapid fluorescent photobleaching ( Figure 2E ).
Selective islet cell staining by monoclonal antibody BISL-32 enabled the rapid identification of the islets using the rhodamine filter (Figure 1, G and H) . Switching to the fluorescence filter permitted an immediate assessment and scoring of the islet cell immunofluorescent staining ( Figure  1 , land J).
DISCUSSION
Protein A is derived from the cell wall of a bacterium, Staphyloccus aureus, and has the property of attaching to the Fc portion of immunoglobulin molecules of several species. 20 In man, protein A reactivity is confined to the lgG1, lgG2, and lgG4 subclasses. Human IgA and IgM proteins are generally negative, though proteins of the human lgA2 subclass react with staphylococci and some IgM proteins (provisionally designated lgM2) are also reactive. IgD and IgE immunoglobulin classes are also unreactive. This selective immunoglobulin binding property of protein A has found increasing application in numerous immunochemical techniques, including its recent use in immunocytochemistry. 21 The use of protein A conjugated to the fluorochrome FITC as a probe to identify the binding of human anti-islet cell antibodies specifically to the endocrine pancreatic islet cells has two important advantages: (1) In comparison with the standard techniques that employ polyclonal anti-immunoglobulin sera derived from various animals, the ICA-pA technique offers a reduction in the interfering background acinar pancreatic staining, thereby enhancing the specificity of the islet cell immunofluorescence (i.e., increased signal/noise ratio). The most likely mechanism for the improvement observed in the ICA-pA assay system seems to be the class/ subclass distribution of the anti-islet antibody reactivity in human sera from type I diabetic subjects. Apparently, most, if not all, of the anti-islet cell specific reactivity resides in the protein A binding immunoglobulin class/subclasses, whereas the interfering background acinar cell reactivity resides in the non-protein A binding fraction (i.e., IgM). (Preliminary studies using immunoglobulin subclass-specific monoclonal antibodies tend to confirm these observations and indicate a paucity of IgM-ICA response even during the preclinical phase of type I diabetes [M. A. K. Omar, S. Srikanta, and G. S. Eisenbarth, submitted for publication].) Elimination of the anti-acinar cell reactivity of the irrelevant antibody components present in the immunized animal sera (anti-immunoglobulin conjugates) is an additional advantage of the ICA-pA system. (2) The second important advantage of the ICA-pA technique is the chemically pure nature of the FITC protein A. This reagent can be easily prepared in large quantities with a uniform immunoglobulin binding capacity and FITC content. This should allow the use of an identical second-step reagent (free of the vagaries of animal sera such as nonspecific reactions, instability, loss of immunoreactivity, etc.) in all ICA assays, thus facilitating standardization of the immunofluorescence assay not only within a laboratory but between laboratories. With the exception of an identical human pancreatic substrate, every other component in our assay system (protein A fluorescein conjugate, rhodamine-conjugated monoclonal antibody BISL-32) is amenable to uniform quality and infinite availability.
The main advantage provided by the immediate pre-identification of islets with monoclonal antibody counterstaining seems to be the time saved during the actual visual assessment and scoring of ICA positivity or negativity. By simply alternating between the two filter systems-rhodamine and fluorescein-one can rapidly scan a sample of welldefined islets and quickly score their ICA reaction.
Precise quantitation of circulating levels of islet cell antibodies can be useful for monitoring the course of islet beta cell destruction, 9 and studying the influence of potential immunotherapeutic interventions. Pending the precise biochemical characterization of the target islet cell autoantigens and development of sensitive radioassays for ICA, the quantitative microimmunofluorometric system described in this report represents an approach in this direction.
